Stocks · News reference
Foghorn Therapeutics stock drops as Eli Lilly ends partnership, prompting a 40% workforce cut to extend cash runway into 2029 while pivoting pipeline.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Eli Lilly and Company has begun construction on a $5 billion manufacturing facility near Richmond, Virginia, dedicated to producing antibody-drug conjugate (ADC) medicines.
Bristol Myers Squibb has demonstrated more stable and consistent revenue growth over the past two years, leading in seven of eight quarters. Novo Nordisk experienced significant volatility, with a dramatic 32% revenue spike in Q1 2026 following its Wegovy weight-loss pill launch, but faced sequential declines in Q2 2026 due to pricing pressure and ordering patterns. While Novo Nordisk's GLP-1 portfolio drives investor interest, its heavy dependence on Ozempic and Wegovy (70% of sales) presents concentration risk compared to Bristol Myers Squibb's more diversified growth portfolio.
Vanguard Health Care ETF (VHT) and iShares U.S. Healthcare ETF (IYH) both provide U.S. healthcare sector exposure with identical 5-year returns, but VHT offers significantly better value with 411 holdings, a lower 0.09% expense ratio versus IYH's 0.37%, and a higher 1.4% dividend yield. While IYH takes a more concentrated approach with 100 stocks focused on large-cap healthcare companies, VHT is recommended for most investors seeking lower costs and broader diversification.
Novo Nordisk, a Denmark-based pharmaceutical leader in diabetes and obesity markets, has faced recent setbacks but could bounce back over the next decade. The company's pipeline includes promising candidates like CagriSema, Amycretin, and UBT251 that could drive growth. However, patent expirations in 2032, increased competition, and regulatory uncertainties present significant challenges. Despite these risks, the analyst views Novo as an attractive long-term buy with potential for competitive returns, especially with dividend reinvestment.